PleoPharma

Executive Summary

PleoPharma is a private, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, with a focus on developing small molecule therapies for central nervous system (CNS) disorders and substance abuse. Founded in 2016, the company's lead program targets Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome (CWS), having successfully completed Phase 2 clinical trials. With the increasing legalization of cannabis and rising rates of CUD, PleoPharma's candidate addresses a significant unmet medical need, positioning the company in a niche but growing market. The company is currently preparing for pivotal Phase 3 studies and potential regulatory interactions.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 3 trial for CUD/CWS70% success
• Q2 2026FDA End-of-Phase 2 meeting85% success
• Q2 2026Publication of Phase 2 results in peer-reviewed journal90% success